The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression

Gilad, Nechama; Zukerman, Hila; Pick, Marjorie; Gatt, Moshe E.

doi:10.18632/oncotarget.27190

Cited by 12 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD24, which was originally identified as a B cell differentiation marker (100), has been indicated as a CSC marker in several tumors, such as ovarian (101), colorectal (102), bladder (103) and urothelial (104) cancers. CD24 has been directly correlated with disease progression and metastasis (59,60,105,106). CD24 is a glycoprotein having both N-and O-linked type glycosylation and linked to glycosylphosphatidylinositol (61).…”

Section: Glycosylation Of Csc Markersmentioning

confidence: 99%

Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies

Khan

Cabral

2021

Front. Oncol.

View full text Add to dashboard Cite

Cancer stem cell (CSCs) are deemed as one of the main reasons of tumor relapse due to their resistance to standard therapies. Numerous intracellular signaling pathways along with extracellular features are crucial in regulating CSCs properties, such as heterogeneity, plasticity and differentiation. Aberrant glycosylation of these cellular signaling pathways and markers of CSCs have been directly correlated with maintaining survival, self-renewal and extravasation properties. In this review, we highlight the importance of glycosylation in promoting stemness character of CSCs, and present strategies for targeting abnormal glycosylation to eliminate the resistant CSC population.

show abstract

Section: Glycosylation Of Csc Markersmentioning

confidence: 99%

Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies

Khan

Cabral

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The important role of CD24 protein expression in MM in vitro was confirmed by our group. CD24+ MM PCs were characterized by a less tumorigenic phenotype than CD24− MM PCs [ 11 ]. Previous publications have shown that CD24 mRNA expression is correlated with good prognosis [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival

Even‐Zohar

Pick

Hofstetter

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Surface antigens are commonly used in flow cytometry assays for the diagnosis of multiple myeloma (MM). Some of these are directly involved in MM pathogenesis or interactions with the microenvironment, but most are used for either diagnostic or prognostic purposes. In a previous study, we showed that in-vitro, CD24-positive plasma cells exhibit a less tumorigenic phenotype. Here, we assessed the prognostic importance of CD24 expression in patients newly diagnosed with MM as it correlates to their clinical course. Immunophenotyping by flow cytometry of 124 patients uniformly treated by a bortezomib-based protocol was performed. The expression of CD24, CD117, CD19, CD45, and CD56 in bone marrow PCs was tested for correlations to clinical parameters. None of the CD markers correlated with the response rates to first-line therapy. However, patients with elevated CD24+ expression on their PCs at diagnosis had a significantly longer PFS (p = 0.002) and OS (p = 0.044). In contrast, the expression of CD117, CD56, or CD45 was found to have no prognostic value; CD19 expression was inversely correlated with PFS alone (p ˂ 0.001) and not with OS. Thus, elevated CD24 expression on PCs appears to be strongly correlated with survival and can be used as a single-surface antigenic prognostic factor in MM.

show abstract

“…In MM PC, CD24 mRNA has been shown to be downregulated, correlated to worse OS [ 12 ]. We found that by upregulating CD24 expression in MM cell lines, the cells were less tumorigenic in their phenotype, as assessed by their impaired capability to migrate and to create colonies in culture [ 113 ]. The decreased tumorigenicity correlated with a “more normal” PC immunophenotype in patients with MM and correlated with CD45 expression [ 113 ].…”

Section: Introductionmentioning

confidence: 99%

“…We found that by upregulating CD24 expression in MM cell lines, the cells were less tumorigenic in their phenotype, as assessed by their impaired capability to migrate and to create colonies in culture [ 113 ]. The decreased tumorigenicity correlated with a “more normal” PC immunophenotype in patients with MM and correlated with CD45 expression [ 113 ]. Furthermore, following immunophenotype analysis in 124 MM patients treated with bortezomib, cyclophosphamide, and dexamethasone, we found that elevated CD24 expression on PC at diagnosis correlated significantly with longer PFS and OS (Gross Even-Zohar N, et al, submitted).…”

Section: Introductionmentioning

confidence: 99%

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

Lebel

Nachmias

Pick

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to the bone marrow matrix and stromal cells, while others are involved in intercellular interactions that result in differentiation of B-cells to plasma cells (PC). These interactions are also involved in malignant transformation of the normal PC to MM PC as well as disease progression. Here, we review selected surface antigens that are commonly used in the flow cytometry analysis of MM for identification of plasma cells (PC) and the discrimination between normal and malignant PC as well as prognostication. These include the markers: CD38, CD138, CD45, CD19, CD117, CD56, CD81, CD27, and CD28. Furthermore, we will discuss the novel marker CD24 and its involvement in MM. The bioactivity of each antigen is reviewed, as well as its expression on normal vs. malignant PC, prognostic implications, and therapeutic utility. Understanding the role of these specific surface antigens, as well as complex co-expressions of combinations of antigens, may allow for a more personalized prognostic monitoring and treatment of MM patients.

show abstract

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression

Cited by 12 publications

References 43 publications

Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies

Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

Contact Info

Product

Resources

About